# Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System

Study · id `cardio:ct-nct03788590` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03788590](<https://clinicaltrials.gov/study/NCT03788590>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03788590

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 133 participants.

## Technical summary

Registry record NCT03788590. Allocation not applicable; no masking; primary purpose treatment. Start 2019-02-23 (anticipated); primary completion 2021-11-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 133 participants (planned count; ClinicalTrials.gov record NCT03788590, source copy `cardio:ctgov-nct03788590-2019-01-08`, retrieved 2026-10-26)
- Planned start: 2019-02-23 (anticipated) (ClinicalTrials.gov record NCT03788590, source copy `cardio:ctgov-nct03788590-2019-01-08`, retrieved 2026-10-26)
- Primary completion: 2021-11-23 (anticipated) (ClinicalTrials.gov record NCT03788590, source copy `cardio:ctgov-nct03788590-2019-01-08`, retrieved 2026-10-26)
- Completion: 2021-12-30 (anticipated) (ClinicalTrials.gov record NCT03788590, source copy `cardio:ctgov-nct03788590-2019-01-08`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03788590-2019-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System
- Acronym: TAVI
- Condition: Severe Aortic Stenosis
- Condition: Aortic Regurgitation
- Intervention (Device): Jenscare TAVI
- Lead sponsor: Ningbo Jenscare Biotechnology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 7cb10f151feb838926a60bc1a7d72cca1fb655d4aa20cb148ee7008fde5e665c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
